Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 4 , ISSUE 2 ( May-August, 2012 ) > List of Articles

REVIEW ARTICLE

Cancer Endometrium: An Update

Piyush Kumar, Jai Kishan Goel

Citation Information : Kumar P, Goel JK. Cancer Endometrium: An Update. J South Asian Feder Obs Gynae 2012; 4 (2):75-84.

DOI: 10.5005/jp-journals-10006-1179

Published Online: 01-08-2012

Copyright Statement:  Copyright © 2012; The Author(s).


Abstract


PDF Share
  1. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
  2. Cancer statistics 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36.
  3. ACOG practice bulletin, clinical management guidelines for obstetriciangynecologists, Number 65, August 2005: Management of endometrial cancer. Obstet Gynecol 2005; 106:413-25.
  4. Abnormal uterine bleeding and prognosis of endometrial cancer. Int J Gynaecol Obstet 2004;85:145-90.
  5. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA 1998;280:1510-17.
  6. Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol Oncol 2002; 86:28-33.
  7. Radiologic staging in patients with endometrial cancer: A meta-analysis. Radiology 1999; 212:711-18.
  8. Evaluation of depth of myometrial invasion and overall staging in endometrial cancer: comparison of diffusion-weighted and dynamic contrastenhanced MR imaging. Radiology 2012;262:530-37.
  9. Endometrial cancer. Lancet 2005;366:491-505.
  10. Cancer of the uterine corpus. In: Edmonds DK (Ed). Dewhurst's textbook of obstetrics and gynaecology (7th ed). Blackwell Publishing 2007.
  11. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009; 105: 103-04.
  12. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987;60:2035-41.
  13. Surgical staging in endometrial cancer: Clinical-pathologic findings of a prospective study. Obstet Gynecol 1984;63:825-32.
  14. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): A randomised study. Lancet 2009; 373:125-36.
  15. Endometrial cancer—revisiting the importance of pelvic and para-aortic lymph nodes. Gynecol Oncol 2007;104:222-31.
  16. Selective pelvic and periaortic lymphadenectomy does not increase morbidity in surgical staging of endometrial carcinoma. Am J Obstet Gynecol 1992;167:1225-30.
  17. Postoperative complications after pelvic lymphadenectomy for the surgical staging of endometrial cancer. J Surg Oncol 2001;78:232-37.
  18. Forwards through the rear-view mirror. Gynecol Oncol 2009;115:1-3.
  19. Is lymphatic mapping in uterine cancer feasible? Ann Surg Oncol 2008;15:1815-17.
  20. Laparoscopically assisted versus open surgery for endometrial cancer—a meta-analysis of randomized controlled trials. Int J Gynecol Cancer 2008; 18:1315-25.
  21. Laparoscopic hysterectomy in the treatment of endometrial cancer: A systematic review. J Minim Invasive Gynecol 2008;15:395-401.
  22. Comparison of laparoscopy and laparotomy for management of endometrial carcinoma: A metaanalysis. Int J Gynecol Cancer 2009;19:400-06.
  23. Comparative performance of the 2009 international federation of gynecology and obstetrics’ staging system for uterine corpus cancer. Obstet Gynecol 2010;116:1141-49.
  24. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A gynecologic oncology group study. Gynecol Oncol 1991;40:55-65.
  25. Adenocarcinoma of the endometrium. Analysis of 256 cases with disease limited to the uterine corpus: Treatment comparisons. Cancer 1983;52: 1026-31.
  26. A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: Toward improving individualized cancer care. Gynecol Oncol 2010;116:399-403.
  27. Stage I corpus cancer: is teletherapy necessary? Am J Obstet Gynecol 1997;176:777-88.
  28. Conservative management of stage I endometrial carcinoma after surgical staging. Gynecol Oncol 2002;84:194-200.
  29. Pathologic models to predict outcome for women with endometrial adenocarcinoma: The importance of the distinction between surgical stage and clinical stage: A Gynecologic oncology group study. Cancer 1996;77:1115-21.
  30. Does size matter? Tumor size and morphology as predictors of nodal status and recurrence in endometrial cancer. Gynecol Oncol 2005;99:564-70.
  31. American Joint Committee on Cancer Staging Manual (7th ed). In: Edge SB, Byrd DR, Compton CC, et al. (Eds), Springer, New York, 2010:403-08.
  32. The impact of age on longterm outcome in patients with endometrial cancer treated with postoperative radiation. Gynecol Oncol 2006;103:87-93.
  33. Is endometrial carcinoma intrinsically more aggressive in elderly patients? Cancer 2003;98:2368-77.
  34. Age as a prognostic factor for recurrence in patients with endometrial carcinoma. Gynecol Oncol 2000;79:79-85.
  35. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: A 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol 2006; 103:714-18.
  36. Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: A Gynecologic Oncology Group Study. Cancer 2010;116:355-61.
  37. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2004;92:744-51.
  38. Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: No need for externalbeam radiotherapy in low and intermediate risk patients. Gynecol Oncol 2007;107:541-48.
  39. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial. PORTEC Study Group. Postoperative radiation therapy in endometrial carcinoma. Lancet 2000;355:1404-11.
  40. Progestagens for endometrial cancer. Cochrane Database Syst Rev 2000;CD001040.
  41. Cancer of the endometrium. Br J Cancer 2001;84(Suppl 2):31-36.
  42. Available at: http://www.nccn.org . (Accessed on October 2, 2012).
  43. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium. Int J Radiat Oncol Biol Phys 2000;48:779-90.
  44. Impact of ethnicity on the incidence of high-risk endometrial carcinoma. Gynecol Oncol 1997;65:8-12.
  45. The racial disparity in outcomes in endometrial cancer: Could this be explained on a molecular level? Gynecol Oncol 2006;102:440-46.
  46. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 1991;164:15-21.
  47. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 2005;63:834-38.
  48. ASTEC/EN.5 Study Group. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): Pooled trial results, systematic review and meta-analysis. Lancet 2009;373:137-46.
  49. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the postoperative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol 2011;29:1692-700.
  50. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: First results of the randomized PORTEC-2 trial. J Clin Oncol 2009;27:3547-56.
  51. Role of intracavitary cuff boost after adjuvant external irradiation in early endometrial carcinoma. Int J Radiat Oncol Biol Phys 1990;19:49-54.
  52. Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium. Gynecol Oncol 1995;57: 138-44.
  53. The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer. Int J Gynecol Cancer 1994;4:84-93.
  54. Stage IC adenocarcinoma of the endometrium: Survival comparisons of surgically staged patients with and without adjuvant radiation therapy. Gynecol Oncol 2003;89:295-300.
  55. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA 2006;295:389-97.
  56. The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: A patient care evaluation study from the American College of Surgeons National Cancer Data Base. Gynecol Oncol 2005;99:530-35.
  57. Adjuvant radiotherapy and survival outcomes in early-stage endometrial cancer: A multi-institutional analysis of 608 women. Gynecol Oncol 2006; 103:661-66.
  58. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 1992;47:179-85.
  59. Improved survival of Asians with corpus cancer compared with whites: An analysis of underlying factors. Obstet Gynecol 2006;107:329-35.
  60. What is the incidence of isolated paraaortic nodal recurrence in grade 1 endometrial carcinoma? Gynecol Oncol 2008;111:46-48.
  61. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate-and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008;108:226-33.
  62. Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: Unraveling a mystery. Gynecol Oncol 2009;115:18-25.
  63. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: Results of a randomised trial. Br J Cancer 2006;95:266-71.
  64. The significance of adnexal involvement in endometrial carcinoma. Gynecol Oncol 1999;74:74-79.
  65. Stage III adenocarcinoma of the endometrium: Two prognostic groups. Gynecol Oncol 1980;9:12-17.
  66. Outcome of endometrial carcinoma patients with involvement of the uterine serosa. Gynecol Oncol 2001;82:338-43.
  67. Radiation therapy for surgically proven para-aortic node metastasis in endometrial carcinoma. Int J Radiat Oncol Biol Phys 1992;24:229-33.
  68. Node-positive adenocarcinoma of the endometrium: Outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol 2009;115:6-11.
  69. Adjuvant radiation therapy in stage III node-positive uterine cancer. Gynecol Oncol 2009;115:239-43.
  70. Analysis of FIGO Stage IIIC endometrial cancer patients. Gynecol Oncol 2001;81:273-78.
  71. Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. Int J Radiat Oncol Biol Phys 2001;50:1154-60.
  72. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2006;24: 36-44.
  73. Treatment of nodepositive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br J Cancer 1997;75:1836-41.
  74. Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: A sequential approach. Int J Radiat Oncol Biol Phys 2007;67:110-16.
  75. A randomized phase III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991) (abstract). J Clin Oncol 2007;25:275
  76. Surgically staged highrisk endometrial cancer: Randomized study of adjuvant radiotherapy alone vs sequential chemo-radiotherapy. Gynecol Oncol 2008;110:190-95.
  77. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2004;22:2159-66.
  78. A randomized trial of progestogens in the primary treatment of endometrial carcinoma. Br J Obstet Gynaecol 1988;95:166-74.
  79. Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations. Acta Obstet Gynecol Scand 1984;63:441-50.
  80. Treatment of FIGO (1971) stage I endometrial carcinoma with intensive surgery, radiotherapy and hormonotherapy according to pathological prognostic groups. Long-term results of a randomised multicentre study. Eur J Cancer 1993;29A:1133-40.
  81. The morbidity of treatment for patients with stage I endometrial cancer: Results from a randomized trial. Int J Radiat Oncol Biol Phys 2001;51:1246-55.
  82. Medically inoperable stage I adenocarcinoma of the endometrium treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 1987;13: 483-88.
  83. Surgical resection of recurrent endometrial carcinoma. Gynecol Oncol 2006; 102:480-88.
  84. Salvage cytoreductive surgery for recurrent endometrial cancer. Gynecol Oncol 2006;103:281-87.
  85. Surgical treatment of recurrent endometrial carcinoma. Cancer 2004;100:89-96.
  86. Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: A multi-institutional experience. Int J Gynecol Cancer 2007;17:886-89.
  87. Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol 1999;75:99-102.
  88. Pelvic exenteration, University of Michigan: 100 patients at 5 years. Obstet Gynecol 1989;74:934-43.
  89. Pelvic exenteration for recurrent gynecologic malignancy: Survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol 2005;99:153-59.
  90. Definitive radiotherapy in the management of isolated vaginal recurrences of endometrial cancer. Int J Radiat Oncol Biol Phys 2005;63: 500-04.
  91. Isolated vaginal recurrences in endometrial carcinoma: Treatment results using high-dose-rate intracavitary brachytherapy and external beam radiotherapy. Gynecol Oncol 1997;66:300-07.
  92. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Phys 2003;56:1366-72.
  93. Survival after relapse in patients with endometrial cancer: Results from a randomized trial. Gynecol Oncol 2003;89:201-09.
  94. Hormone therapy in advanced and recurrent endometrial cancer: A systematic review. Int J Gynecol Cancer 2007;17:964-78.
  95. Hormonal therapy of endometrial cancer. Eur J Cancer 2005;41:673-75.
  96. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 2001;19: 364-67.
  97. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol 2007;106:325-33.
  98. Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 1984;17:285-91.
  99. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: A gynecologic oncology group study. J Clin Oncol 2004;22:3902-08.
  100. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: Definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 2003;14:441-48.
  101. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 1994;12:1408-14.
  102. What is the best chemotherapy regimen in recurrent or advanced endometrial carcinoma? Preliminary results (abstract). Proc Am Soc Clin Oncol 2003;22:453
  103. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: A Gynecologic Oncology Group study. Ann Oncol 2004;15:1173-78.
  104. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2008;108:3-9.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.